Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (91-100 of 205) with videos related to

Pageof 21
Sort By:
Cancer Research and Treatment|July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung CancerMakoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB studyIbiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2016
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 SkippingRebecca S Heist, Lecia V Sequist, Darrell Borger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibRyohei Katayama, Luc Friboulet, Sumie Koike, et al.
Lung Cancer (Auckland, N.Z.)|February 4, 2020
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (<i>ALK</i>)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 StudiesShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
JTO Clinical and Research Reports|July 11, 2022
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on CrizotinibJaime L Schneider, Alona Muzikansky, Jessica J Lin, et al.
Genes & Development|March 21, 2007
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesisAlice T Shaw, Alexander Meissner, James A Dowdle, et al.
Pageof 21

Showing results (91-100 of 205) with videos related to

Sort By:
Pageof 21
Cancer Research and Treatment|July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung CancerMakoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB studyIbiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2016
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 SkippingRebecca S Heist, Lecia V Sequist, Darrell Borger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibRyohei Katayama, Luc Friboulet, Sumie Koike, et al.
Lung Cancer (Auckland, N.Z.)|February 4, 2020
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (<i>ALK</i>)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 StudiesShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
JTO Clinical and Research Reports|July 11, 2022
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on CrizotinibJaime L Schneider, Alona Muzikansky, Jessica J Lin, et al.
Genes & Development|March 21, 2007
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesisAlice T Shaw, Alexander Meissner, James A Dowdle, et al.
Pageof 21